Bristol Myers Squibb Co (BMY) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Bristol Myers Squibb reported revenue of $48.19B, down 0.2% from $48.30B the year before. Net income was $7.05B (a 14.6% net margin), or $3.46 per diluted share. Gross margin was 71.1% and operating margin was 32.7%. Operating activities generated $14.16B of cash, leaving $12.85B of free cash flow. At fiscal year end, Bristol Myers Squibb held $90.04B in total assets against $71.53B in total liabilities, including $10.21B of cash and equivalents.
Open the full interactive Bristol Myers Squibb financials → Quarterly statements, key ratios, valuation history and price charts.
Bristol Myers Squibb Key Stats
| Share Price | $56.67 |
|---|---|
| Market Cap | $116.06B |
| P/E Ratio | 16.4 |
| Dividend Yield | 4.39% |
| Revenue YoY Growth | -0.2% |
| 52-Week Range | $40.79 – $67.39 |
| Shares Outstanding | 2.04 billion (basic, 2026 Q2) |
Bristol Myers Squibb Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $42.52B | $46.38B | $46.16B | $45.01B | $48.30B | $48.19B |
| Cost of Goods Sold | $11.77B | $9.94B | $10.14B | $10.69B | $13.97B | $13.94B |
| Gross Profit | $30.75B | $36.45B | $36.02B | $34.31B | $34.33B | $34.26B |
| Operating Income | $10.95B | $16.10B | $17.40B | $15.84B | $13.26B | $15.74B |
| Pre-Tax Income | -$6.87B | $8.10B | $7.71B | $8.44B | -$8.38B | $9.33B |
| Income Tax | $2.12B | $1.08B | $1.37B | $400.0M | $554.0M | $2.27B |
| Net Income | -$9.02B | $6.99B | $6.33B | $8.03B | -$8.95B | $7.05B |
| Diluted EPS | -$3.99 | $3.12 | $2.95 | $3.86 | -$4.41 | $3.46 |
Bristol Myers Squibb Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $12.22B | $12.50B | $11.49B | $12.97B |
| Net Income | $2.20B | $1.09B | $2.68B | $3.32B |
| Diluted EPS | $1.08 | $0.53 | $1.31 | $1.62 |
Bristol Myers Squibb Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $14.55B | $13.98B | $9.12B | $11.46B | $10.35B | $10.21B |
| Current Assets | $30.19B | $33.26B | $27.27B | $31.77B | $29.78B | $29.39B |
| Total Assets | $118.48B | $109.31B | $96.82B | $95.16B | $92.60B | $90.04B |
| Current Liabilities | $19.08B | $21.87B | $21.89B | $22.26B | $23.77B | $23.42B |
| Total Long-Term Debt | $50.34B | $44.37B | $38.95B | $39.53B | $49.43B | $44.83B |
| Total Liabilities | $80.60B | $73.31B | $65.70B | $65.67B | $76.22B | $71.53B |
| Shareholders' Equity | $37.82B | $35.95B | $31.06B | $29.43B | $16.34B | $18.47B |
Bristol Myers Squibb Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $14.05B | $16.21B | $13.07B | $13.86B | $15.19B | $14.16B |
| Cash From Investing | -$10.86B | -$538.0M | -$1.06B | -$2.29B | -$21.35B | -$4.13B |
| Cash From Financing | -$1.15B | -$16.22B | -$16.96B | -$9.42B | $5.13B | -$10.35B |
| Free Cash Flow | $13.30B | $15.23B | $11.95B | $12.65B | $13.94B | $12.85B |
| Dividends Paid | $4.08B | $4.40B | $4.63B | $4.74B | $4.86B | $5.04B |
Figures from Bristol Myers Squibb's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Bristol Myers Squibb financials page for every line item.
Bristol Myers Squibb Company Profile
| Ticker | BMY |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | Princeton, New Jersey |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0000014272 |
Frequently Asked Questions
What was Bristol Myers Squibb's revenue in fiscal 2025?
Bristol Myers Squibb (BMY) reported revenue of $48.19B for fiscal 2025.
What is Bristol Myers Squibb's annual revenue history?
Bristol Myers Squibb's annual revenue by fiscal year: 2020: $42.52B; 2021: $46.38B; 2022: $46.16B; 2023: $45.01B; 2024: $48.30B; 2025: $48.19B.
What was Bristol Myers Squibb's net income in fiscal 2025?
Bristol Myers Squibb reported net income of $7.05B for fiscal 2025.
What was Bristol Myers Squibb's earnings per share (EPS) in fiscal 2025?
Bristol Myers Squibb's diluted EPS was $3.46 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Bristol Myers Squibb generate in fiscal 2025?
Bristol Myers Squibb generated $12.85B of free cash flow in fiscal 2025.
What was Bristol Myers Squibb's revenue last quarter?
In its most recent reported quarter (2026 Q2), Bristol Myers Squibb reported revenue of $12.97B.
How much debt does Bristol Myers Squibb have?
Bristol Myers Squibb reported $44.83B of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Bristol Myers Squibb are outstanding?
Bristol Myers Squibb reported a weighted average of 2.04 billion basic shares outstanding in 2026 Q2.
What is Bristol Myers Squibb's market cap?
Based on its latest closing price, Bristol Myers Squibb (BMY) has a market capitalization of about $116.06B.
When does Bristol Myers Squibb's fiscal year end?
Bristol Myers Squibb's fiscal year end, as registered with the SEC, is December 31.
Where is Bristol Myers Squibb headquartered?
Bristol Myers Squibb lists its business address in Princeton, New Jersey in its SEC filings.